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Clinical trials engrafting human fetal ventral mesencephalic tissue have demonstrated,
in principle, that cell replacement therapy provides substantial long-lasting improvement
of motor impairments generated by Parkinson’s Disease (PD). The use of fetal tissue
is not practical for widespread clinical implementation of this therapy, but stem cells
are a promising alternative source for obtaining replacement cells. The ideal stem
cell source has yet to be established and, in this review, we discuss the potential
of neural stem cells in the adult subventricular zone (SVZ) as an autologous source
of replacement cells. We identify three key challenges for further developing this
potential source of replacement cells: (1) improving survival of transplanted cells, (2)
suppressing glial progenitor proliferation and survival, and (3) developing methods to
efficiently produce dopaminergic neurons. Subventricular neural stem cells naturally
produce a dopaminergic interneuron phenotype that has an apparent lack of vulnerability to
PD-mediated degeneration. We also discuss whether olfactory bulb dopaminergic neurons
derived from adult SVZ neural stem cells are a suitable source for cell replacement
strategies.
Keywords: subventricular zone, olfactory bulb, neural stem cells, adult neurogenesis, dopaminergic, cell
replacement therapy
INTRODUCTION
Parkinson’s Disease (PD) is one of the most prevalent neurode-
generative disorders and afflicts ∼1% of the population over
60 years of age in industrialized nations (Nussbaum and Ellis,
2003). PD affects several regions of the nervous system that
result in many clinical symptoms (Braak et al., 2004; Poewe,
2008). The most characteristic symptoms, however, are motor
system impairments that include tremor, rigidity, and bradyki-
nesia. The pathology underlying these motor symptoms is a
progressive degeneration of dopaminergic neurons in the sub-
stantia nigra pars compacta. These dopamine neurons modulate
control of motor function through axonal projections to the puta-
men and caudate divisions of the striatum. Standard clinical care
is focused on the functional preservation of this nigrostriatal cir-
cuit. Pharmacological approaches with L-DOPA and dopamine
receptor agonists can ameliorate most motor symptoms, partic-
ularly in the early stages after a clinical diagnosis. As the disease
progresses, however, medication regimens become less effective
and surgical strategies, such as deep brain stimulation, can pro-
vide symptomatic relief. Both the pharmacological and surgical
interventions ultimately fail though because they do not stop the
progressive degeneration of midbrain dopaminergic neurons.
Cell replacement strategies are a fundamentally different
type of therapy because they introduce new dopaminergic
neurons that can restore striatal dopamine levels. Clinical
trials engrafting human fetal ventral mesencephalic tissue
containing dopaminergic neuronal progenitors into the stria-
tum demonstrated, in principle, that this approach can pro-
vide substantial long-lasting improvement of motor symptoms
(Widner et al., 1992; Defer et al., 1996; Freed et al., 2001; Mendez
et al., 2002; Olanow et al., 2003). Some patients in these trials
improved post-operatively to a point where L-DOPA therapy was
no longer required, but others experienced negligible long-term
improvement and, in some cases, severe graft-induced dyskinesias
developed and required additional surgical intervention.
IDEAL FEATURES OF REPLACEMENT CELL SOURCES
Analyses of the clinical trials identified several features of replace-
ment cells that are essential for favorable functional outcomes
(Wijeyekoon and Barker, 2009; Lindvall and Bjorklund, 2011).
These features include establishing replacement cell sources that
are autologous, or at the least allogenic, since immunosuppres-
sion appears to improve engrafted cell survival and clinical out-
comes (Olanow et al., 2003). The survival rate of transplanted
cells is an important practical issue and sources that provide
replacement cells with higher survival rates reduce the total
amount of donor material required. Significant clinical benefit
is estimated to require the survival of at least 100,000 engrafted
dopaminergic neurons per putamen (Hagell and Brundin, 2001).
Clinical improvement is also more likely achieved with sources
that can be used as dissociated cell suspensions. Unlike solid tissue
grafts, cell suspensions can readily disperse and evenly inner-
vate target areas. Studies of engraftments in both humans and
rodents indicate the uneven and patchy reinnervation of the puta-
men promotes the development of adverse dyskinesia side effects
(Ma et al., 2002; Carlsson et al., 2006; Maries et al., 2006). The
risk of dyskinesias is also reduced with replacement cell sources
that can be prepared by standardized protocols that minimize
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the presence of undesired phenotypes. The presence of sero-
tonergic progenitors in fetal mesencephalic tissue, for example,
is believed to contribute to the incidence of transplant-related
dyskinesias (Politis et al., 2012). Consistent with this possibil-
ity, serotonergic neurons transplanted into the striatum of rodent
PD models exacerbate dyskinesias induced by L-DOPA (Carlsson
et al., 2007).
EMBRYONIC AND INDUCED PLURIPOTENT STEM CELL
SOURCES
The ideal source of replacement cells for PD has not been estab-
lished (reviewed in Meyer et al., 2010). Fetal mesencephalic tissue
is not practical because of the difficulty in standardizing donor
tissue and ethical concerns of how to generate the necessary
amounts of material required for widespread clinical use. Stem
cells, however, are a promising source of replacement cells that
meet the requirements for creating favorable clinical outcomes
(discussed above). Several studies have demonstrated the feasi-
bility of stem cell based therapies using embryonic stem cells
(Bjorklund et al., 2002; Kim et al., 2002; Takagi et al., 2005;
Roy et al., 2006; Rodriguez-Gomez et al., 2007; Cho et al., 2008;
Sanchez-Pernaute et al., 2008; Friling et al., 2009). These studies
used a variety of differentiation protocols, but they all showed that
transplants of embryonic stem cell-derived dopaminergic neu-
rons into either rodent or primate PDmodel systems both survive
and integrate into the host circuitry to provide significant func-
tional recovery. Embryonic stem cells face several important chal-
lenges, however, before they can be considered for human clinical
trials. These challenges include developing higher efficiency pro-
tocols for dopaminergic neuron production, improving survival
of engrafted cells, and methods to completely remove contam-
inating cell types responsible for tumor or teratoma formation
observed in animal trials.
Induced pluripotent stem cells are another potential source of
replacement cells. Their broad differentiation potential resembles
embryonic stem cells, but the ability to derive these cells from
adult tissue avoids the moral and ethical issues of using embry-
onic stem cell lines. Furthermore, induced pluripotent stem cells
are a potential autologous source of replacement cells since they
can be generated from a patient’s own cells. Recent reports indi-
cate that dopaminergic neurons derived from induced pluripo-
tent stem cells can survive and provide functional improvement
in rodent PD model systems (Wernig et al., 2008; Hargus et al.,
2010; Swistowski et al., 2010; Rhee et al., 2011; Chang et al., 2012;
Sundberg et al., 2013). Advancing induced pluripotent stem cells
to a clinical setting faces many of same challenges confronting
the use of embyronic stem cells, including improvement in the
dopaminergic neuron yields and prevention of tumor formation
in the recipient.
REPLACEMENT CELLS DERIVED FROM THE ADULT SVZ
ADULT NEURAL STEM CELLS
Neural stem cells are an alternative source of replacement neu-
rons. These cells lack the pluripotent potential of embryonic and
induced pluripotent stem cells, but they also do not have the
same teratoma or tumor forming potential. Fetal tissue is a rich
source of neural stem cells that can generate a wide array of neu-
ronal phenotypes, but as discussed above, the use of fetal tissue
is fraught with moral and ethical problems. By contrast, adult
neural stem cells do not have these issues, although they typi-
cally generate a more limited number of neuronal phenotypes.
In the adult mammalian brain, there are two well-established
neurogenic niches: the hippocampal subgranular zone and the
subventricular zone (SVZ) of the lateral ventricles (Gage et al.,
2008; Seki et al., 2011). Neurons generated in both of these
regions are able to integrate into pre-existing neural circuitry,
which makes them attractive candidates for cell replacement ther-
apy. Progenitors generated in the subgranular zone migrate to the
dentate gyrus and become excitatory glutamatergic granule cells.
Subgranular zone neural stem cells are located within the interior
of the hippocampus, however, and extracting them without dam-
aging the hippocampus is difficult. SVZ neural stem cells almost
exclusively produce inhibitory GABAergic inhibitory interneuron
progenitors that migrate to the olfactory bulb glomerular and
granule cells layers (production of a small number of excitatory
neurons has also been reported in Brill et al., 2009). SVZ neural
stem cells reside within the walls of the lateral ventricle and, by
penetrating non-eloquent parts of the brain in humans, they can
be endoscopically harvested, expanded in vitro and differentiated
into both neuronal and glial progenitors (Westerlund et al., 2005).
Thus, adult SVZ neural stem cells are a potential clinically feasible
source of autologous replacement neurons.
TRANSPLANTATION OF ADULT SVZ CELLS INTO THE STRIATUM
Several studies have homochronously transplanted either SVZ
tissue explants or suspensions of either neurospheres or disso-
ciated cells into the adult rodent striatum (Table 1) (Lois and
Alvarez-Buylla, 1994; Herrera et al., 1999; Zhang et al., 2003;
Meissner et al., 2005; Richardson et al., 2005; Seidenfaden et al.,
2006; Chen et al., 2007a,b; Shim et al., 2007; Deleidi et al.,
2011). Similar to other sources of donor cells, the survival rates
of transplanted SVZ cells were consistently low. Also similar to
clinical trials with fetal tissue, migration of transplanted SVZ
cells away from the injection site was greater with dispersed
SVZ cultures or neurospheres than with engraftments of tissue
explants.
An unexpected and consistent finding in the rodent studies
with SVZ-derived cells was the meager differentiation and sur-
vival of transplanted neurons. Using either cell suspensions or
tissue explants as donor material, many of the surviving cells
displayed glial phenotypes and very few expressed markers of
mature neurons. The poor neuron yields were surprising since the
adult SVZ normally produces large numbers of neuronal progen-
itors (Luskin, 1993; Lois and Alvarez-Buylla, 1994). Analyses of
SVZ progenitor cultures expanded in vitro found a large percent-
age of cells expressed glial marker genes prior to transplantation
(Richardson et al., 2005; Chen et al., 2007b), suggesting that
in vitro culture conditions may preferentially select for glial pre-
cursors. An exception is a study by Zhang and co-workers that
reported achieving a high percentage (∼70%) of neuronal pre-
cursors in SVZ cultures prior to transplantation (Zhang et al.,
2003). A majority of cells that survived a month after trans-
plantation were found to have a mature a neuronal phenotype
and only a few cells expressed the glial marker GFAP. The rea-
sons for higher levels of neuronal generation and survival in this
study are unclear. The interactions between adult SVZ neural
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stem cells and their surrounding niche are complex and only
just becoming understood (reviewed in Ihrie and Alvarez-Buylla,
2011). Despite their poor neuronal differentiation and survival,
transplants of SVZ-derived cells into the host striatum did pro-
vide some functional recovery in 6-hydroxydopamine lesioned
rodent PD models a month after surgery (Meissner et al., 2005;
Richardson et al., 2005). The extent of the improvement was vari-
able, but it does suggest that introduction of glia is not deleterious
and may produce some short-term symptomatic improvement.
DOPAMINERGIC DIFFERENTIATION OF SVZ PROGENITORS
In addition to the poor differentiation and survival of neurons
with SVZ-cell transplants, few, if any, of the detectable neu-
rons displayed dopaminergic features. The human clinical trials
clearly showed that integration and survival of dopaminergic neu-
rons is essential for sustained long-term functional improvement.
Embryonic and induced pluripotent stem cells can be directed
toward a dopaminergic cell fate by culturing them with appro-
priate growth factors and morphogens (Kriks and Studer, 2009;
Boyer et al., 2012). Similar protocols can significantly improve
neuronal progenitor yields in cultured SVZ cells, but they do not
direct these cells to a dopaminergic cell fate (Deleidi et al., 2011).
These protocols can generate dopaminergic neurons, however, if
the SVZ progenitors are first converted into pluripotent stem cells
by Oct4 over-expression (Deleidi et al., 2011). Oct4 has a central
role in stem cell pluripotency and differentiation, and is sufficient
to reprogram adult neural stem cells into pluripotent stem cells
(Pesce and Scholer, 2001; Kim et al., 2009). About 5% of the total
cells in culture can be directed to adopt a midbrain dopaminergic
neuronal phenotype when SVZ progenitors are reprogrammed
by Oct4 over-expression. Transplantation of cultures with these
reprogrammed dopaminergic neurons into 6-hydroxydopamine
lesioned rats produced significant and reproducible functional
improvement for up to 2 months after the procedure (Deleidi
et al., 2011).
An alternative genetic engineering strategy for improving
dopaminergic neuron yields is to over-express transcription fac-
tors that specify cell fate during normal development. This
approach has been successfully used with both embryonic and
induced pluripotent stem cells (Chung et al., 2002, 2005; Kim
et al., 2002; Andersson et al., 2006; Martinat et al., 2006; Friling
et al., 2009; Sanchez-Danes et al., 2012; Theka et al., 2013).
Both Mash-1 and Nurr1 genes encode transcription factors that
are involved in the specification of midbrain dopaminergic neu-
rons (Park et al., 2006). Retroviral-mediated over-expression
of these transcription factors can direct a substantial percent-
age (∼37%) of the total number of cultured adult SVZ cells
to express dopaminergic neuronal markers (Shim et al., 2007).
Transplantation of these cells in 6-hydroxydopamine lesioned rats
also produces robust functional improvement.
SVZ/OLFACTORY BULB DOPAMINERGIC PHENOTYPE AS A POTENTIAL
REPLACEMENT CELL SOURCE
Adult SVZ neural stem cells normally generate dopaminergic
interneurons and both Mash1 and Nurr1-family transcription
factors are important for specification of these interneurons (Cave
and Baker, 2009). Although the over-expression of Mash1 and
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Nurr1 was intended to generate dopaminergic neurons with a
midbrain phenotype, this strategy may have generated either A16
olfactory bulb dopaminergic neurons or hybrid A16 neurons. The
ability of the dopaminergic neurons generated by Shim and co-
workers to significantly improve functional performance in the
rodent PD model, raises the possibility that either an A16 or a
hybrid A16 dopaminergic neuron is a viable alternative for cell
replacement strategies.
Non-midbrain dopaminergic neurons are not typically consid-
ered for replacement cells in PD. This is due, in part, to studies
of transplanted dopaminergic neurons from non-mesencepahlic
brain regions. Grafts of diencephalic dopaminergic neurons from
either rodent or human embryonic hypothalamic tissue poorly
integrated into the host striatum and provided no significant
functional benefit in PD models (Abrous et al., 1988; Zuddas
et al., 1991; Frodl et al., 1994). Furthermore, previous clinical
trials grafting tissue containing catecholaminergic neurons from
non-brain regions, including the adrenal medulla, carotid body,
retinal epithelium and sympathetic ganglion neurons, demon-
strated either only marginal or no significant benefit. In addition,
morbidities associated some procedures, such as autografts of
either adrenal medulla and sympathetic ganglia, have further
discouraged exploration of non-midbrain phenotypes as replace-
ment cells (reviewed in Wijeyekoon and Barker, 2009).
Olfactory bulb dopaminergic neurons have several favor-
able attributes, however, that are distinct from these previously
tested non-midbrain phenotypes. Like other adult-generated
neurons, olfactory bulb dopaminergic progenitors can integrate
into pre-existing neural circuitry. Mature neurons are likely
able to innervate large areas of striatum since they have pro-
cesses that typically extend for over 200μm and, in some cases,
over 700μm (Kiyokage et al., 2010). Like their counterparts in
the substantia nigra, a prominent electrophysiological property
of olfactory bulb dopaminergic neurons is a capacity to gen-
erate auto-rhythmic action potentials (Pignatelli et al., 2005;
Guzman et al., 2009). Unlike the substantia nigra, however,
olfactory bulb dopaminergic neurons are not vulnerable in PD-
mediated neurodegeneration (Huisman et al., 2004). Consistent
with this reduced vulnerability, olfactory bulb dopaminergic neu-
rons lack α-synuclein deposits in rodents over-expressing this
protein (Ubeda-Banon et al., 2010). Several PD patients surviv-
ing at least 10 years after intrastriatal grafts of fetal mesencephalic
tissue have shown accumulation of α-synuclein in grafted neu-
rons (Kordower et al., 2008a,b; Li et al., 2008, 2010; Mendez et al.,
2008). Whether this accumulation adversely affects the function
or survival of replacement neurons is not known, but it does
suggest that replacement neurons of the midbrain phenotype are
susceptible to PD in the long-term. Replacement neurons with the
olfactory bulb dopaminergic phenotype, however, are expected to
be less vulnerable to this pathology.
CHALLENGES FOR DEVELOPING ADULT SVZ CELLS AS REPLACEMENT
CELLS
Developing adult SVZ cells into a clinically suitable autologous
source of replacement neurons faces several challenges. One
challenge is to enhance survival rates of engrafted cells. Studies
with embryonic and induced pluripotent stem cells, for which
long-term survival is also an issue, have indicated that treating
the donor cells with antioxidants or growth factors can increase
survival rates (Nakao et al., 1994; Apostolides et al., 1998; Espejo
et al., 2000; Hoglinger et al., 2001; Andereggen et al., 2009).
The presence of neurotransmitters in the culture conditions may
improve the ability to expand and differentiate cells with neuronal
phenotypes since neurotransmitters can modulate proliferation,
migration and survival of SVZ-derived cells in the endogenous
SVZ neurogenic niche (reviewed in Young et al., 2011). In addi-
tion, pre-conditioning recipients by administering growth factors
may also be an important strategy to improve long-term sur-
vival (Chen et al., 2007a). Elucidating culture conditions that
promote neuronal progenitor expansion and survival will be criti-
cal for developing standardized preparations to generate clinically
suitable replacement cells from adult SVZ neural stem cells.
A second challenge is the suppression of glial progenitor prolif-
eration and survival. SVZ neural stem cells prodigiously generate
neuronal progenitors in their endogenous niche, but most of
the progenitors generated by these cells either do not to sur-
vive or they adopt alternative fates when cultured in vitro and
transplanted into the striatum. Furthermore, proportional lev-
els of glial production increase with either the age of the SVZ
neural stem cell donor or the length of time that the stem cells
are cultured (Gritti et al., 2009). Since most PD patients are
advanced in age, the propensity of autologously derived SVZ
stem cells to produce glia is an important challenge to address.
Protocols for in vitro expansion of SVZ progenitors typically use
growth factor combinations that include epidermal growth fac-
tor (EGF) (Deleyrolle and Reynolds, 2009). The inclusion of this
growth factor, however, may be detrimental for neuronal progen-
itor production since stimulation of EGF receptors promotes glial
progenitor proliferation and differentiation in the SVZ (Aguirre
and Gallo, 2007; Gonzalez-Perez and Quinones-Hinojosa, 2010;
Gonzalez-Perez and Alvarez-Buylla, 2011). Alternatively, culture
media may require other growth factors to suppress glial differ-
entiation. Expansion of neurospheres derived from the adult SVZ
in media containing both EGF and FGF9 enhances neuronal pro-
liferation while diminishing both oligodendrocyte and astrocyte
progenitor production (Lum et al., 2009). Supplementing in vitro
culture conditions with Noggin may also enhance suppression
of glial phenotypes. SVZ neural stem cells and neural progen-
itors express BMP receptors and antagonism of these recep-
tors by Noggin inhibits glial differentiation (Lim et al., 2000).
Furthermore, cell-sorting techniques can facilitate the removal of
glial progenitors from SVZ-derived cultures prior to transplanta-
tion. Recent studies with human pluripotent progenitors showed
that glial progenitors can be successfully isolated from mixed cul-
tures based on co-expression of CD44 and CD184 (Yuan et al.,
2011).
A third challenge is developing efficient methods to produce
dopaminergic neurons. Treatment either with growth factors,
morphogens, signalingmolecules, or chromatinmodifying agents
does not direct SVZ-derived progenitors toward a dopamin-
ergic fate. By contrast, significant dopaminergic neuron pro-
duction has been only achieved through genetic modification
of SVZ-derived progenitors (Shim et al., 2007; Deleidi et al.,
2011). These genetic engineering methods, however, come with
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some caveats. Reprogramming of SVZ neural stem cells into
pluripotent cells prior to dopaminergic differentiation intro-
duces the same safety concerns associated with induced pluripo-
tent stem cell strategies. Retroviral transduction of SVZ pro-
genitors to over-express transcription factor genes, such as
Nurr1 and Mash1, avoids the concerns of genetic reprogram-
ming, but retroviruses are questionable for clinical applica-
tion since they can increase the risk of tumor formation by
disrupting endogenous gene expression upon their insertion
into the host genome (Yi et al., 2011). Genetically engineering
SVZ progenitors for cell replacement therapy in PD will likely
require one of the other available methods to transduce cells
(Lowry and Plath, 2008).
Even though over-expression of Nurr1 and Mash1 has pro-
vided the best yield of SVZ-derived dopaminergic neurons to
date, only a subset of transduced cells adopted a dopaminergic
phenotype. This partial induction may reflect the heterogeneity
within the SVZ stem cell niche. Specific subsets of olfactory bulb
interneurons are generated from the neural stem cells that are spa-
tially localized in distinct regions of the adult SVZ (Kelsch et al.,
2007; Merkle et al., 2007; Young et al., 2007; Brill et al., 2009).
Further studies are required to establish whether adult SVZ neural
stem cells from spatially distinct regions are limited in their capac-
ity to generate dopaminergic progenitors in vitro. In addition
to transcription factors, heterogeneous expression of microRNAs
may also be instrumental in shaping the in vitro potential of adult
SVZ neural stem cells to generate dopaminergic neurons (De
Chevigny et al., 2012). Further studies are also required to address
whether the dopaminergic neurons produced with SVZ-derived
progenitors either adopt an olfactory bulb, midbrain or a hybrid
dopaminergic phenotype. As discussed above, the olfactory bulb
phenotype may be clinically advantageous for replacement cells,
but one concern is that olfactory bulb dopaminergic interneu-
rons also co-express of GABA (Kiyokage et al., 2010). The effect
of GABA in these potential replacement cells is difficult to pre-
dict, but recent studies suggest that nigral dopaminergic neurons
inhibit striatal output through the co-release of both dopamine
and GABA (Tritsch et al., 2012). Consistent with this observa-
tion, about 10% of dopaminergic neurons in substantia nigra pars
compacta are reported to co-express mRNA for the GABA biosyn-
thetic enzyme glutamate decarboxylase 65 (Gonzalez-Hernandez
et al., 2001). Thus, the co-expressed GABAergic phenotype in
olfactory bulb dopaminergic interneurons may be more of a simi-
larity than a difference with nigral dopaminergic neurons. Studies
in rodent PD animal models are needed, however, to demonstrate
whether the olfactory bulb or a hybrid dopaminergic phenotype
can provide functional recovery without producing deleterious
side effects.
CONCLUSIONS
The adult SVZ is a promising source of neural stem cells to
generate dopaminergic neuronal progenitors for cell transplant
strategies in PD. Since these stem cells can be endogenously har-
vested from patients, they are a potential autologous source of
replacement cells. As discussed in this review, however, there are
several important technical issues to be addressed in order for
adult SVZ neural stem cells to be competitive source for clinically
suitable dopaminergic neurons.
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